News Related to Propionic Acidemia

Related coverage linked through entity extraction aliases.

Moderna Advances Rare Disease Pipeline Amid FDA Vaccine Debate and Cost Reductions

Feb 25, 2026

Moderna partners with Recordati on propionic acidemia therapy for up to $160 million, while FDA Commissioner defends mRNA vaccine support following funding cuts and regulatory challenges.

Moderna Reports Q4 2025 Results, Cuts Costs 30% Amid FDA Flu Vaccine Setback

Feb 13, 2026

Moderna reported Q4 2025 revenue of $700 million and full-year revenue of $1.9 billion, beating estimates while cutting operating expenses by $2.2 billion. The FDA refused to file the company's seasonal flu vaccine application.